Breast Cancer - Pipeline Review, H2 2016

  • ID: 4015286
  • Report
  • 3149 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3-D Matrix Ltd
  • Advantagene Inc
  • Alissa Pharma
  • Antigen Express Inc
  • Arvinas Inc
  • Avexxin AS
  • MORE
Breast Cancer - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Breast Cancer (Oncology) pipeline landscape.

Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy.

Report Highlights:

The Pharmaceutical and Healthcare latest pipeline guide Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively.

Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Breast Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Breast Cancer (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Breast Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3-D Matrix Ltd
  • Advantagene Inc
  • Alissa Pharma
  • Antigen Express Inc
  • Arvinas Inc
  • Avexxin AS
  • MORE
Introduction

Breast Cancer Overview

Therapeutics Development

Breast Cancer - Therapeutics under Development by Companies

Breast Cancer - Therapeutics under Investigation by Universities/Institutes

Breast Cancer - Pipeline Products Glance

Breast Cancer - Products under Development by Companies

Breast Cancer - Products under Investigation by Universities/Institutes

Breast Cancer - Companies Involved in Therapeutics Development

Breast Cancer - Therapeutics Assessment

Drug Profiles

Breast Cancer - Dormant Projects

Breast Cancer - Discontinued Products

Breast Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Breast Cancer, H2 2016

Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Development by Companies, H2 2016 (Contd..4)

Number of Products under Development by Companies, H2 2016 (Contd..5)

Number of Products under Development by Companies, H2 2016 (Contd..6)

Number of Products under Development by Companies, H2 2016 (Contd..7)

Number of Products under Development by Companies, H2 2016 (Contd..8)

Number of Products under Development by Companies, H2 2016 (Contd..9)

Number of Products under Development by Companies, H2 2016 (Contd..10)

Number of Products under Development by Companies, H2 2016 (Contd..11)

Number of Products under Development by Companies, H2 2016 (Contd..12)

Number of Products under Development by Companies, H2 2016 (Contd..13)

Number of Products under Development by Companies, H2 2016 (Contd..14)

Number of Products under Development by Companies, H2 2016 (Contd..15)

Number of Products under Development by Companies, H2 2016 (Contd..16)

Number of Products under Development by Companies, H2 2016 (Contd..17)

Number of Products under Development by Companies, H2 2016 (Contd..18)

Number of Products under Development by Companies, H2 2016 (Contd..19)

Number of Products under Development by Companies, H2 2016 (Contd..20)

Number of Products under Development by Companies, H2 2016 (Contd..21)

Number of Products under Development by Companies, H2 2016 (Contd..22)

Number of Products under Development by Companies, H2 2016 (Contd..23)

Number of Products under Development by Companies, H2 2016 (Contd..24)

Number of Products under Development by Companies, H2 2016 (Contd..25)

Number of Products under Development by Companies, H2 2016 (Contd..26)

Number of Products under Development by Companies, H2 2016 (Contd..27)

Number of Products under Development by Companies, H2 2016 (Contd..28)

Number of Products under Development by Companies, H2 2016 (Contd..29)

Number of Products under Development by Companies, H2 2016 (Contd..30)

Number of Products under Development by Companies, H2 2016 (Contd..31)

Number of Products under Development by Companies, H2 2016 (Contd..32)

Number of Products under Development by Companies, H2 2016 (Contd..33)

Number of Products under Development by Companies, H2 2016 (Contd..34)

Number of Products under Development by Companies, H2 2016 (Contd..35)

Number of Products under Development by Companies, H2 2016 (Contd..36)

Number of Products under Development by Companies, H2 2016 (Contd..37)

Number of Products under Development by Companies, H2 2016 (Contd..38)

Number of Products under Development by Companies, H2 2016 (Contd..39)

Number of Products under Development by Companies, H2 2016 (Contd..40)

Number of Products under Development by Companies, H2 2016 (Contd..41)

Number of Products under Investigation by Universities/Institutes, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..7)

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..8)

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Development by Companies, H2 2016 (Contd..6)

Products under Development by Companies, H2 2016 (Contd..7)

Products under Development by Companies, H2 2016 (Contd..8)

Products under Development by Companies, H2 2016 (Contd..9)

Products under Development by Companies, H2 2016 (Contd..10)

Products under Development by Companies, H2 2016 (Contd..11)

Products under Development by Companies, H2 2016 (Contd..12)

Products under Development by Companies, H2 2016 (Contd..13)

Products under Development by Companies, H2 2016 (Contd..14)

Products under Development by Companies, H2 2016 (Contd..15)

Products under Development by Companies, H2 2016 (Contd..16)

Products under Development by Companies, H2 2016 (Contd..17)

Products under Development by Companies, H2 2016 (Contd..18)

Products under Development by Companies, H2 2016 (Contd..19)

Products under Development by Companies, H2 2016 (Contd..20)

Products under Development by Companies, H2 2016 (Contd..21)

Products under Development by Companies, H2 2016 (Contd..22)

Products under Development by Companies, H2 2016 (Contd..23)

Products under Development by Companies, H2 2016 (Contd..24)

Products under Development by Companies, H2 2016 (Contd..25)

Products under Development by Companies, H2 2016 (Contd..26)

Products under Development by Companies, H2 2016 (Contd..27)

Products under Development by Companies, H2 2016 (Contd..28)

Products under Development by Companies, H2 2016 (Contd..29)

Products under Development by Companies, H2 2016 (Contd..30)

Products under Development by Companies, H2 2016 (Contd..31)

Products under Development by Companies, H2 2016 (Contd..32)

Products under Development by Companies, H2 2016 (Contd..33)

Products under Development by Companies, H2 2016 (Contd..34)

Products under Development by Companies, H2 2016 (Contd..35)

Products under Development by Companies, H2 2016 (Contd..36)

Products under Development by Companies, H2 2016 (Contd..37)

Products under Development by Companies, H2 2016 (Contd..38)

Products under Development by Companies, H2 2016 (Contd..39)

Products under Development by Companies, H2 2016 (Contd..40)

Products under Development by Companies, H2 2016 (Contd..41)

Products under Development by Companies, H2 2016 (Contd..42)

Products under Development by Companies, H2 2016 (Contd..43)

Products under Development by Companies, H2 2016 (Contd..44)

Products under Development by Companies, H2 2016 (Contd..45)

Products under Development by Companies, H2 2016 (Contd..46)

Products under Development by Companies, H2 2016 (Contd..47)

Products under Development by Companies, H2 2016 (Contd..48)

Products under Development by Companies, H2 2016 (Contd..49)

Products under Development by Companies, H2 2016 (Contd..50)

Products under Development by Companies, H2 2016 (Contd..51)

Products under Development by Companies, H2 2016 (Contd..52)

Products under Development by Companies, H2 2016 (Contd..53)

Products under Development by Companies, H2 2016 (Contd..54)

Products under Development by Companies, H2 2016 (Contd..55)

Products under Development by Companies, H2 2016 (Contd..56)

Products under Development by Companies, H2 2016 (Contd..57)

Products under Development by Companies, H2 2016 (Contd..58)

Products under Development by Companies, H2 2016 (Contd..59)

Products under Development by Companies, H2 2016 (Contd..60)

Products under Development by Companies, H2 2016 (Contd..61)

Products under Development by Companies, H2 2016 (Contd..62)

Products under Development by Companies, H2 2016 (Contd..63)

Products under Development by Companies, H2 2016 (Contd..64)

Products under Development by Companies, H2 2016 (Contd..65)

Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..7)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..8)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..9)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..10)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..11)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..12)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..13)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..14)

Breast Cancer - Pipeline by 3-D Matrix Ltd, H2 2016

Breast Cancer - Pipeline by 3-V Biosciences Inc, H2 2016

Breast Cancer - Pipeline by 3SBio Inc, H2 2016

Breast Cancer - Pipeline by 4SC AG, H2 2016

Breast Cancer - Pipeline by A&G Pharmaceutical Inc, H2 2016

Breast Cancer - Pipeline by AB Science SA, H2 2016

Breast Cancer - Pipeline by AbbVie Inc, H2 2016

Breast Cancer - Pipeline by AbGenomics International Inc, H2 2016

Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016

Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016

Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016

Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016

Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016

Breast Cancer - Pipeline by Aduro BioTech Inc, H2 2016

Breast Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016

Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016

Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016

Breast Cancer - Pipeline by Advantagene Inc, H2 2016

Breast Cancer - Pipeline by Advaxis Inc, H2 2016

Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016

Breast Cancer - Pipeline by Aegis Therapeutics LLC, H2 2016

Breast Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016

Breast Cancer - Pipeline by Aerpio Therapeutics Inc, H2 2016

Breast Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016

Breast Cancer - Pipeline by Affichem SA, H2 2016

Breast Cancer - Pipeline by Agenus Inc, H2 2016

Breast Cancer - Pipeline by Agilvax Inc, H2 2016

Breast Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016

Breast Cancer - Pipeline by Alchemia Ltd, H2 2016

Breast Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016

Breast Cancer - Pipeline by Alissa Pharma, H2 2016

Breast Cancer - Pipeline by Almac Discovery Ltd, H2 2016

Breast Cancer - Pipeline by Alteogen Inc, H2 2016

Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016

Breast Cancer - Pipeline by Ambrx Inc, H2 2016

Breast Cancer - Pipeline by American Gene Technologies International Inc, H2 2016

Breast Cancer - Pipeline by Amgen Inc, H2 2016

Breast Cancer - Pipeline by Ampio Pharmaceuticals Inc, H2 2016

Breast Cancer - Pipeline by Amplyx Pharmaceuticals Inc, H2 2016

Breast Cancer - Pipeline by Angion Biomedica Corp, H2 2016

Breast Cancer - Pipeline by ANP Technologies Inc, H2 2016

Breast Cancer - Pipeline by AntiCancer Inc, H2 2016

Breast Cancer - Pipeline by Antigen Express Inc, H2 2016

Breast Cancer - Pipeline by Antoxis Ltd, H2 2016

Breast Cancer - Pipeline by Aphios Corp, H2 2016

Breast Cancer - Pipeline by APIM Therapeutics AS, H2 2016

Breast Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016

Breast Cancer - Pipeline by Aravive Biologics Inc, H2 2016

Breast Cancer - Pipeline by ARMO Biosciences Inc, H2 2016

Breast Cancer - Pipeline by Armour Therapeutics Inc, H2 2016

Breast Cancer - Pipeline by Arno Therapeutics Inc, H2 2016

Breast Cancer - Pipeline by ArQule Inc, H2 2016

Breast Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016

Breast Cancer - Pipeline by Arvinas Inc, H2 2016

Breast Cancer - Pipeline by Asana BioSciences LLC, H2 2016

Breast Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016

Breast Cancer - Pipeline by AskAt Inc, H2 2016

Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016

Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016

Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016

Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016

List of Figures

Number of Products under Development for Breast Cancer, H2 2016

Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3-D Matrix Ltd
  • 3-V Biosciences Inc
  • 3SBio Inc
  • 4SC AG
  • A&G Pharmaceutical Inc
  • AB Science SA
  • AbbVie Inc
  • AbGenomics International Inc
  • Acceleron Pharma Inc
  • Acetylon Pharmaceuticals Inc
  • Adaptimmune Therapeutics Plc
  • ADC Therapeutics Sarl
  • Adgero Biopharmaceuticals Inc
  • Aduro BioTech Inc
  • Advanced Accelerator Applications SA
  • Advanced Cancer Therapeutics
  • Advanced Proteome Therapeutics Corp
  • Advantagene Inc
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Aegis Therapeutics LLC
  • Aeglea BioTherapeutics Inc
  • Aerpio Therapeutics Inc
  • Aeterna Zentaris Inc
  • Affichem SA
  • Agenus Inc
  • Agilvax Inc
  • Aileron Therapeutics Inc
  • Alchemia Ltd
  • Alethia Biotherapeutics Inc
  • Alissa Pharma
  • Almac Discovery Ltd
  • Alteogen Inc
  • Amarna Therapeutics BV
  • Ambrx Inc
  • American Gene Technologies International Inc
  • Amgen Inc
  • Ampio Pharmaceuticals Inc
  • Amplyx Pharmaceuticals Inc
  • Angion Biomedica Corp
  • ANP Technologies Inc
  • AntiCancer Inc
  • Antigen Express Inc
  • Antoxis Ltd
  • Aphios Corp
  • APIM Therapeutics AS
  • Aptevo Therapeutics Inc
  • Aravive Biologics Inc
  • ARMO Biosciences Inc
  • Armour Therapeutics Inc
  • Arno Therapeutics Inc
  • ArQule Inc
  • Arrien Pharmaceuticals LLC
  • Arvinas Inc
  • Asana BioSciences LLC
  • Ascentage Pharma Group Corp Ltd
  • AskAt Inc
  • Aslan Pharmaceuticals Pte Ltd
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Athenex Inc
  • ATLAB Pharma SAS
  • Atossa Genetics Inc
  • AVEO Pharmaceuticals Inc
  • Avexxin AS
  • Azaya Therapeutics Inc
  • Basilea Pharmaceutica Ltd
  • Batu Biologics Inc
  • Bavarian Nordic A/S
  • Bayer AG
  • BCN Biosciences LLC
  • BeiGene Ltd
  • Bellicum Pharmaceuticals Inc
  • Berg LLC
  • BerGenBio AS
  • Beta Pharma Inc
  • Bexion Pharmaceuticals LLC
  • BeyondSpring Pharmaceuticals Inc
  • Bicycle Therapeutics Ltd
  • Bio-Path Holdings Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll